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ABSTRACT
Background. PALOMA-2 confirmed that first-line palbociclib +
letrozole improved progression-free survival (hazard ratio, 0.58;
95% confidence interval, 0.46–0.72) in postmenopausal women
with estrogen receptor–positive (ER+)/human epidermal growth
factor receptor 2–negative (HER2−) advanced breast cancer
(ABC). This analysis evaluated palbociclib-associated hemato-
logic adverse events (AEs) and provides insight on managing
these AEs.
Materials and Methods. Postmenopausal women with ER
+/HER2− ABC were randomly assigned 2:1 to letrozole (2.5 mg
daily continuously) plus oral palbociclib (125 mg daily; 3 weeks
on/1 week off) or placebo. Safety assessments were per-
formed at baseline, days 1 and 15 (first two cycles) and day
1 of subsequent cycles, and included white blood cell, platelet,
and absolute neutrophil count (ANC).
Results. PALOMA-2 randomized 666 women to palbociclib +
letrozole (n = 444) or placebo + letrozole (n = 222). Neutropenia
was the most common AE (95.3%) with palbociclib (grade
3, 55.6%; grade 4, 11.5%) and was managed by dose modifica-
tions; progression-free survival was similar between patients
who experienced grade ≥ 3 neutropenia versus those who did
not. Median (range) time to onset of neutropenia with pal-
bociclib + letrozole was 15 (12–700) days (grade ≥ 3, 28.0
[12–854] days); median duration of each neutropenia episode
grade ≥ 3 was 7.0 days. Asian ethnicity and low baseline ANC
were associated with increased risk of grade 3/4 neutropenia
with palbociclib (p < .001).
Conclusion. Palbociclib + letrozole was generally well tol-
erated. Neutropenia, the most frequently reported AE in
women with ER+/HER2− ABC, was mostly transient and
manageable by dose modifications in patients who experi-
enced grade ≥ 3 neutropenia, without appearing to com-
promise efficacy. (Pfizer; NCT01740427) The Oncologist
2019;24:1514–1525
Implications for Practice: Palbociclib demonstrated an acceptable safety profile in PALOMA-2 in women with estrogen
receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC) receiv-
ing first-line palbociclib + letrozole. Although hematologic adverse events (AEs) are typically expected with anticancer thera-
pies and are often clinically significant, palbociclib-related hematologic AEs, particularly neutropenia (most frequent AE),
were transient/manageable by dose reduction, interruption, or cycle delay, which is in contrast to the more profound neu-
tropenia associated with chemotherapy. Palbociclib dose adjustments decreased hematologic AE severity without appearing
to compromise efficacy, supporting palbociclib + letrozole as a first-line treatment for ER+/HER2− ABC.
Correspondence: Véronique Diéras, M.D., Praticien Spécialiste en Oncologie médicale, Oncologie sénologique, Centre Eugène Marquis Rennes,
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and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adapta-
tions are made.
© 2019 The Authors.
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INTRODUCTION
Treatment guidelines recommend sequential endocrine therapy
as first-line therapy for hormone receptor–positive (HR+)
advanced breast cancer (ABC) [1–3]. Although endocrine ther-
apy is effective, a substantial proportion of women will develop
endocrine resistance and, consequently, require alternative
treatment options, including switching to a different endocrine
therapy or another therapeutic approach [4]. Several targeted
therapies, including the first-in-class cyclin-dependent kinase
4/6 (CDK 4/6) inhibitor palbociclib (Ibrance; Pfizer Inc, New York,
NY), have recently been approved for use in combination with
endocrine therapy [5–8], and guidelines include recommenda-
tions for adding a CDK 4/6 inhibitor in combination with endo-
crine therapy for the treatment of pre- and postmenopausal
women with HR+/human epidermal growth factor receptor 2–
negative (HER2−) ABC [1–3].
Palbociclib is a potent inhibitor of CDK 4/6 that blocks cell
cycle progression from G1 to S phase and subsequent DNA
synthesis [9–11]. Palbociclib is indicated for the treatment of
HR+/HER2− advanced breast cancer as first-line therapy in
combination with an aromatase inhibitor and in the endocrine-
resistant setting in combination with fulvestrant [6, 12].
The efficacy and safety of palbociclib as first-line therapy in
combination with letrozole in patients with endocrine receptor–
positive (ER+)/HER2− ABC was initially demonstrated in the
phase II PALOMA-1 study [13] and subsequently confirmed in
the phase III PALOMA-2 study [14]. Palbociclib plus letrozole sig-
nificantly prolonged median progression-free survival (PFS) ver-
sus placebo plus letrozole in postmenopausal women with ER
+/HER2– ABC (24.8 vs. 14.5 months; hazard ratio, 0.58; 95%
confidence interval [CI], 0.46–0.72; 2-sided p < .001; data cutoff,
February 26, 2016). Although palbociclib significantly improved
outcomes in PALOMA-2, the incidence of myelotoxic events
was higher with palbociclib compared with placebo plus
letrozole (neutropenia, 79.5% vs. 6.3%; leukopenia, 39.0%
vs. 2.3%; anemia, 24.1% vs. 9.0%; thrombocytopenia,
15.5% vs. 1.4%) [14].
Overall, the combination of palbociclib plus endocrine ther-
apy has been shown to have a generally manageable safety
profile in phase II and III clinical trials to date; however, these
trials also reported higher rates of hematologic adverse events
(AEs) versus letrozole or fulvestrant (monotherapy or with pla-
cebo). These hematologic AEs are expected given the mecha-
nism of action of CDK 4/6 inhibitors [15] and are considered to
be an on-target, antiproliferative response in the treatment of
breast cancer. Myelosuppressive events have consistently been
shown with CDK 4/6 inhibitors in clinical trials [13, 15–18]. Ini-
tial phase II clinical trial data show that palbociclib-related
hematologic AEs, including neutropenia, are mostly uncompli-
cated, transient, and generally of short duration [19]. In addi-
tion, a low incidence of febrile neutropenia was reported in
patients receiving palbociclib (0.9%) [20]. Moreover, other ana-
lyses showed that these AEs have been successfully man-
aged via dose reductions (without apparent loss of efficacy)
[14, 20], with no differences in the rate of permanent treat-
ment discontinuations between palbociclib and comparator
treatment arms [14].
To better elucidate the safety profile of palbociclib used in
combination with letrozole, the clinical patterns of hematologic
AEs in PALOMA-2 were evaluated over time, with an
emphasis on neutropenia and the consequences of neutro-
penia (e.g., infection and dose modifications).
MATERIALS AND METHODS
Patients
PALOMA-2 enrolled postmenopausal women with histologically
or cytologically confirmed ER+/HER2− ABC (locoregionally
recurrent or metastatic) who had not received prior systemic
anticancer therapy for ER+ advanced disease. Eligibility criteria
(supplemental online Table 1) and study design have been pre-
viously published [14]. Disposition of patients is shown in sup-
plemental online Figure 1. The protocol was approved by an
institutional review board or independent ethics committee at
each participating site. The study was conducted in accordance
with the Declaration of Helsinki, and all patients provided writ-
ten informed consent.
Study Design
PALOMA-2 (ClinicalTrials.gov, NCT01740427) is an interna-
tional, randomized, double-blind, placebo-controlled, phase III
study designed to assess the efficacy and safety of pal-
bociclib plus letrozole as first-line therapy in postmeno-
pausal women with ER+/HER2− ABC. The data cutoff for
the current analyses was February 26, 2016, and is in line
with the data cutoff from the primary paper [14]. The pri-
mary endpoint was investigator-assessed PFS, defined as
the time from randomization to radiologically confirmed
disease progression (Response Evaluation Criteria in Solid
Tumors, version 1.1 [RECIST] criteria) or death during the
study. Secondary endpoints included a safety evaluation of
patients treated with palbociclib plus letrozole or placebo
plus letrozole.
Treatment
Patients were randomized in a 2:1 ratio to oral palbociclib
125 mg per day plus letrozole 2.5 mg per day or placebo
plus letrozole 2.5 mg per day. Palbociclib was administered
daily on a 4-week cycle (3 weeks on, 1 week off); letrozole
was administered continuously. Stratification factors include
disease site (visceral or nonvisceral), disease-free interval
from end of (neo)adjuvant therapy (de novo metastatic,
≤12 or > 12 months), and prior (neo)adjuvant hormonal
therapy (yes, no). “Visceral” disease referred to any lung
(including pleura) and/or liver involvement, and “non-
visceral” disease referred to absence of lung (including
pleura) and/or liver involvement. There was no stratification
by country or region of the world. Granulocyte colony stimu-
lating factor (G-CSF) was not recommended per protocol but
could be used in accordance with American Society of Clini-
cal Oncology guidelines [1].
Safety Assessment
Adverse event assessment included description of the event,
duration, severity, timing, and seriousness of the AE and its
relatedness to study treatment as reported by the investigator.
© 2019 The Authors.
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Hematologic AEs were based on laboratory data and case
report forms and summarized by worst grade severity. Neutro-
penia was determined based on laboratory tests of absolute
neutrophil counts. Hematologic laboratory results were fur-
ther verified for correct grading.
In the event of adverse reactions, dose reductions of pal-
bociclib or placebo were permitted. Protocol-required dose
modifications for treatment-related toxicities are shown in
Figure 1. No dose adjustment for letrozole was permitted, but
dosing interruptions were allowed. Discontinuations and dose
reduction attributable to neutropenia and other hematologic
AEs were based on data reported on case report forms.
Laboratory safety assessments were conducted at base-
line, on days 1 and 15 of cycles 1 and 2, on day 1 of each
subsequent cycle, and at end of treatment or withdrawal.
Data Analysis
Any patient who received ≥1 dose of study drug was included
in the safety analyses. AEs reported by investigators were
coded by the Medical Dictionary for Regulatory Activities
(MedDRA) version 18.1, and AE severity was graded using the
National Cancer Institute Common Terminology Criteria for
Adverse Events, version 4.0.
Descriptive statistics were used to summarize AE frequen-
cies and the patterns of the AEs experienced by the patients.
AE frequency was summarized based on the maximum toxic-
ity grade for the patient during the treatment as reported by
investigators. For AEs prespecified as being of clinical impor-
tance, the risk difference between the two treatment arms
was calculated, along with their corresponding 95% CI, with-
out adjustment for multiplicity. An overlap of at least 1 day
was required for the analysis evaluating infection (any grade
and grade 3/4) overlapping with neutropenia (any grade and
grade 3/4).
The association between baseline characteristics and
grade 3 or 4 neutropenia was examined for patients in the
palbociclib treatment arm. Univariate analysis was used to
assess the associations of these risk factors with neutropenia,
Figure 1. Dose modification scheme for managing palbociclib/placebo-related toxicities.
Abbreviations: ANC, absolute neutrophil count; ECG, electrocardiogram; QTc, corrected QT.
© 2019 The Authors.
The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.
Palbociclib Hematologic Toxicity Study1516
which are presented as odds ratios with p values reported. A
multivariate logistic analysis was conducted to evaluate poten-
tial risk factors for developing on-treatment neutropenia. The
covariate variables included in the multivariate logistic analysis
were selected based on their clinical relevance and included
prior chemotherapy status, previous radiotherapy status, age,
baseline Eastern Cooperative Oncology Group performance
status, number of disease sites, race, and baseline absolute
neutrophil count.
To evaluate the influence of palbociclib dose reduction,
regardless of cause, on efficacy outcome PFS, landmark analyses
with landmarks at 3, 6, and 9 months were conducted using the
Kaplan-Meier method. In the landmark analysis, patients whose
treatment duration was shorter than the landmark time were
excluded. Patients who experienced dose reduction before the
landmark were assigned to the dose-reduction group, whereas
those not requiring a dose reduction before the landmark were
assigned to the non–dose-reduction group.
RESULTS
Patient Population
A total of 666 patients were enrolled in PALOMA-2 between
February 28, 2013, and July 29, 2014 (palbociclib plus letrozole,
n = 444; placebo plus letrozole, n = 222; supplemental online
Fig. 1). Demographics and baseline characteristics were gener-
ally balanced across both treatment groups and have been
previously published (supplemental online Table 2) [14].
The median (range) duration of treatment was substan-
tially longer in the palbociclib plus letrozole arm compared
with the placebo plus letrozole arm (19.8 [0.033–34.1] vs. 13.6
[0.33–35.2] months). In the palbociclib plus letrozole arm, the
median daily dose of palbociclib was 125 mg, and the median
relative dose intensity was 93.9% (range, 40.3–109.5).
Overall, 55.2% (n = 245) of patients receiving palbociclib
plus letrozole and 72.5% (n = 161) of patients receiving placebo
plus letrozole discontinued study treatment by the cutoff date
for the current analyses. The majority of patients who perma-
nently discontinued study treatment did so because of objec-
tive progressive disease (38.5% for palbociclib plus letrozole
vs. 56.8% for placebo plus letrozole). The second leading cause
of discontinuation from study treatment was the occurrence of
an AE (7.4% for palbociclib plus letrozole vs. 4.5% for placebo
plus letrozole). Overall, 1.4% of patients receiving palbociclib
plus letrozole discontinued palbociclib because of a hematolog-
ical AE, whereas 0.2% of patients discontinued both palbociclib
and letrozole. Treatment-related AEs associated with perma-
nent discontinuation were reported in 5.6% of patients receiv-
ing palbociclib plus letrozole and 1.4% receiving placebo plus
letrozole.
Safety Analysis
Hematologic-Specific Adverse Events: Investigator
Reported
The overall incidence of AEs was comparable between the
two treatment arms (palbociclib plus letrozole, 98.9%; pla-
cebo plus letrozole, 95.5%), with no unexpected AE findings
for palbociclib (supplemental online Table 3). The most
common all-causality AE was neutropenia in the palbociclib
plus letrozole arm (79.5%) and infection in the placebo plus
letrozole arm (42.3%). Grades 3 and 4 neutropenia were
reported in 249 (56.1%) and 46 (10.4%) patients, respectively,
in the palbociclib arm and in 2 (0.9%) and 1 (0.5%) patients in
the placebo arm. Febrile neutropenia was reported in 1.8%
(n = 8; all non-Asian) of patients in the palbociclib plus letrozole
arm and did not result in permanent treatment discontinua-
tion for any patient. Febrile neutropenia was not reported in
the placebo plus letrozole arm. The incidence of serious AEs
(SAEs; all causality, all cycles) was 19.6% in patients receiving
palbociclib plus letrozole (supplemental online Table 4).
Neutropenia was also the most common treatment-related
AE reported in patients receiving palbociclib plus letrozole
(78.4%). Treatment-related serious AEs were reported in 5.4%
(supplemental online Table 4) and 0.9% of the patients in the
palbociclib plus letrozole and placebo plus letrozole arms,
respectively (treatment-related AEs and SAEs were AEs and
SAEs assessed by the investigator as being related to treat-
ment, possibly related to treatment, or unknown if related to
treatment). Overall, the incidence of treatment-related hema-
tologic SAEs was low in patients receiving palbociclib plus
letrozole (≤0.5%; supplemental online Table 4). In only one
patient (palbociclib plus letrozole arm) was neutropenia
assessed as a serious AE; the patient was initially hospitalized
for cellulitis and subsequently developed grade 4 neutropenia
during the hospitalization stay.
Figure 2 shows the risk difference between patients in the
two treatment arms for selected hematologic and non-
hematologic AEs. Patients treated with palbociclib plus letrozole
had a significantly higher risk of experiencing AEs of neutrope-
nia, leukopenia, neutrophil count decreased, anemia, and
thrombocytopenia (all causality, any grade) versus placebo plus
letrozole, as well as of experiencing the nonhematologic AEs of
alopecia, fatigue, and nausea (all causality, any grade).
Hematologic-Specific Toxicities: Neutropenia, Anemia,
and Thrombocytopenia: Assessment of Laboratory Data
The frequency of any-grade neutropenia was higher in the pal-
bociclib plus letrozole arm versus the placebo plus letrozole
arm (95.3% vs. 18.9%), with similar findings for grade 3/4 neu-
tropenia (67.1% vs. 1.4%; Table 1). Median (range) time from
first dose to first episode of any-grade neutropenia was 15.0
(12–700) and 71.0 (13–958) days for palbociclib plus letrozole
and placebo plus letrozole, respectively; time to grade ≥ 3
neutropenia was 28.0 (12–854) and 57.0 (14–197) days (sup-
plemental online Fig. 2). Median (range) duration of a grade ≥ 3
neutropenia episode was 7 (1–115) days for patients receiving
palbociclib plus letrozole and 2.0 (1–15) days for placebo plus
letrozole.
The frequency of grade 3/4 neutropenia was higher in
earlier cycles compared with later cycles. For example, 56.1%
of patients (n = 249) in the palbociclib plus letrozole arm had
grade 3/4 neutropenia in the first four cycles, with 67.5%
(n = 168) of these patients subsequently developing grade
3/4 neutropenia in later cycles. In addition, the percentage
of patients with maximum grade 3 neutropenia in cycles 1–6
was 49.5% (n = 220), whereas only 3.6% (n = 8) of these
patients developed grade 4 neutropenia after the first
6 cycles.
© 2019 The Authors.
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A Kaplan-Meier plot showed that for the majority of
patients, their first experience of grade 3 or 4 neutropenia
occurred within the first 2 or 3 months of treatment (Fig. 3).
Any-grade anemia and thrombocytopenia occurred fre-
quently in the palbociclib plus letrozole arm; however, the
overall incidence was lower than that of neutropenia, and
severity was generally mild to moderate. Median (range)
time from first dose to the first episode of any-grade anemia
was 29.0 (2–760) days for palbociclib plus letrozole. Median
time to onset of first grade ≥ 3 anemia episode was 182.0
(14–760) days (supplemental online Fig. 2) in the palbociclib
plus letrozole arm. Median duration of a grade ≥ 3 episode
of anemia was 7.0 (1–125) days. Median time from first dose
to the first episode of any-grade thrombocytopenia was 26.0
(2–742) days. Median time to onset of first grade ≥ 3 throm-
bocytopenia episode was 283.5 (21–617) days for patients
receiving palbociclib plus letrozole (supplemental online
Fig. 2); no patient in the placebo arm had grade ≥ 3 throm-
bocytopenia. Median duration of a grade ≥ 3 thrombocyto-
penia episode was 7.0 (2–28) days for patients treated with
palbociclib plus letrozole. Of the two patients in the pal-
bociclib group and three patients in the placebo group who
reported an AE of bleeding (i.e., hematoma or hemorrhage),
none experienced thrombocytopenia during the study.
Risk Factors for the Development of Grade 3/4
Neutropenia: Assessment of Laboratory Data
Univariate analysis of laboratory data identified nonwhite
race (odds ratio, 0.314; p < .0001 vs. white), Asian ethnicity
(odds ratio, 4.799; p = .0002 vs. non-Asian), and baseline
absolute neutrophil count <3.68 × 103/mm3 (odds ratio,
0.190; p < .0001) as potential risk factors for developing
grade 3/4 neutropenia for patients receiving palbociclib
plus letrozole (Table 2). No associations were identified
between the risk of developing grade 3/4 neutropenia and
prior chemotherapy or prior radiotherapy (Table 2).
Multivariate analysis confirmed baseline absolute neutro-
phil count <3.68 × 103/mm3 (odds ratio, 0.1814; p < .0001)
as a potential risk factor for developing grade 3/4 neutrope-
nia for patients receiving palbociclib plus letrozole (Table 2).
Neutropenia-Associated Infection
To evaluate clinical outcomes that were potentially associated
with neutropenia, we assessed the overlapping of infection
and neutropenia (using laboratory data) of at least 1 day.
The overlapping of infection and neutropenia occurred in
219 (51.8%) patients in the palbociclib plus letrozole arm, with
the majority (96.5%) of infections being grade 1/2 in severity
(supplemental online Fig. 3). Overlapping grade 3/4 infections
occurred in only 15 (3.4%) patients with neutropenia (all
grades). Among these 15 patients, grade 3/4 infections com-
prised grade 3 urinary tract infection (n = 4); cellulitis (n = 3);
influenza (n = 2); appendicitis, breast cellulitis, bronchitis, viral
gastroenteritis, pneumonia, and sinusitis (n = 1 each); and
grade 4 urosepsis (n = 1). Among the 298 (67%) patients
receiving palbociclib plus letrozole with grade 3/4 neutro-
penia, 93 (31.2%) had overlapping infections (all grades).
Infections (all grades) occurring with an incidence of ≥5%
in patients with grade 3/4 neutropenia included upper
respiratory tract infection (19.4%), nasopharyngitis (18.3%),
urinary tract infection (11.8%), oral herpes (10.8%), sinusi-
tis (9.7%), conjunctivitis (6.5%), herpes zoster (6.5%), and
rhinitis (5.4%). Six (2.0%) patients had an overlapping grade
3 infection (urinary tract infection, n = 2; breast cellulitis, cellu-
litis, influenza, and sinusitis, n = 1 each); no patient had a
grade 4 infection.
Granulocyte colony stimulating factor could be adminis-
tered to patients with treatment-emergent neutropenia. A
total of 10.7% of patients in the palbociclib plus letrozole arm
received G-CSF (8.6%, 1.6%, and 0.5% of patients received fil-
grastim, pegfilgrastim, and lenograstim, respectively).
Figure 2. Risk difference for prespecified adverse events of clinical importance (hematologic and nonhematologic: all causalities, all
cycles, as-treated population).
Abbreviations: AE, adverse event; CI, confidence interval.
© 2019 The Authors.
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Table 1. Summary of key hematologic laboratory abnormalities
AEs
Palbociclib plus
letrozole (n = 444)a
Placebo plus
letrozole (n = 222)a
Neutropeniab
Any grade, n (%) 423 (95.3) 42 (18.9)
Maximum grade, n (%)
1 20 (4.5) 30 (13.5)
2 105 (23.7) 9 (4.1)
3 247 (55.6) 2 (0.9)
4 51 (11.5) 1 (0.5)
Episodes per patient, n (%)
1 18 (4.1) 25 (11.3)
2 22 (5.0) 7 (3.2)
3–5 85 (19.1) 5 (2.3)
≥ 6 298 (67.1) 5 (2.3)
Median duration by episode (range),c d
Any grade 26.0 (1–590) 28.0 (1–84)
Grade 1–2 28.0 (1–590) 28.0 (1–84)
Grade ≥ 2 14.0 (1–504) 28.0 (1–71)
Grade ≥ 3 7.0 (1–115) 2.0 (1–15)
Grade 4 7.0 (1–115) 15.0 (15–15)
Median time from first dose to onset of first episode (range), d
Any grade 15.0 (12–700) 71.0 (13–958)
Grade ≥ 2 15.0 (12–700) 63.0 (13–372)
Grade ≥ 3 28.0 (12–854) 57.0 (14–197)
Grade 4 31.0 (14–673) 14.0 (14–14)
Anemiac
Any grade, n (%) 305 (68.7) 70 (31.5)
Maximum grade, n (%)
1 192 (43.2) 56 (25.2)
2 87 (19.6) 9 (4.1)
3 26 (5.9) 5 (2.3)
4 0 0
Episodes per patient, n (%)
1 79 (17.8) 39 (17.6)
2 59 (13.3) 14 (6.3)
3–5 92 (20.7) 14 (6.3)
≥ 6 75 (16.9) 3 (1.4)
Median duration by episode (range),c d
Any grade 28.0 (1–798) 28.0 (1–505)
Grade 1–2 28.0 (1–798) 28.0 (1–505)
Grade ≥ 2 28.0 (1–477) 28.0 (1–166)
Grade ≥ 3 7.0 (1–125) 13.0 (1–40)
Grade 4 NA NA
Median time from first dose to onset of first episode (range), d
Any grade 29.0 (2–760) 71.5 (14–813)
Grade ≥ 2 90.0 (6–760) 225.0 (14–645)
Grade ≥ 3 182.0 (14–760) 477.0 (43–645)
Grade 4 NA NA
(continued)
© 2019 The Authors.
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Table 1. (continued)
AEs
Palbociclib plus
letrozole (n = 444)a
Placebo plus
letrozole (n = 222)a
Thrombocytopeniad
Any grade, n (%) 269 (60.6) 24 (10.8)
Maximum grade, n (%)
1 237 (53.4) 22 (9.9)
2 24 (5.4) 2 (0.9)
3 6 (1.4) 0
4 2 (0.5) 0
Episodes per patient, n (%)
1 69 (15.5) 14 (6.3)
2 48 (10.8) 5 (2.3)
3–5 84 (18.9) 4 (1.8)
≥ 6 68 (15.3) 1 (0.5)
Median duration by episode (range),c d
Any grade 14.0 (1–675) 28.0 (1–420)
Grade 1–2 14.0 (1–675) 28.0 (1–420)
Grade ≥ 2 7.0 (1–172) 3.5 (1–6)
Grade ≥ 3 7.0 (2–28) NA
Grade 4 15.5 (3–28) NA
Median time from first dose to onset of first episode (range), d
Any grade 26.0 (2–742) 126.5 (14–477)
Grade ≥ 2 141.0 (14–659) 56.5 (14–99)
Grade ≥ 3 283.5 (21–617) NA
Grade 4 323.0 (29–617) NA
Abbreviations: AE, adverse event; NA, not applicable.
aBased on laboratory data.
bNeutropenia was determined based on laboratory tests of absolute neutrophil counts.
cFor duration of hematologic abnormality by grade, all episodes are counted; in cases of multiple episodes, the duration for all episodes were
added and used in the calculation.
dAnemia and thrombocytopenia include subjects with postbaseline Common Terminology Criteria for Adverse Events (CTCAE) grade > 0 and
greater than baseline CTCAE grade.
Figure 3. Kaplan-Meier curve showing cumulative incidences of grade 3/4 neutropenia (assessed by laboratory data) in patients
treated with palbociclib plus letrozole.
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Effect of Dose Reduction and Neutropenia Severity
on Efficacy Endpoints
Permanent treatment discontinuation from the study as a
result of either all-causality neutropenia (n = 5 [1.1%]) or
decreased neutrophil count (n = 2 [0.5%]) was observed in
patients receiving palbociclib plus letrozole (Table 3). Febrile
neutropenia, leukopenia, anemia, and thrombocytopenia did
not result in permanent discontinuation of study treatment in
either treatment arm. Patients receiving palbociclib plus
letrozole had an increased frequency of temporary study
treatment discontinuation because of neutropenia (54.7%
vs. 0.9%), decreased neutrophil count (13.3% vs. 0.5%), febrile
neutropenia (1.6% vs. 0%), or thrombocytopenia (1.1% vs.
0.5%) compared with those receiving placebo plus letrozole.
Among patients with all-causality AEs associated with dose
reduction in the palbociclib plus letrozole arm, 67.5% (108 of
160 patients) had a dose reduction associated with neutrope-
nia (24.3% of patients in the palbociclib plus letrozole arm
vs. 0.5% of patients in the placebo plus letrozole arm; Table 3),
14.4% (23 of 160 patients) had a dose reduction associated
Table 2. Risk of developing grade 3 or 4 neutropeniaa by clinical characteristics in patients receiving palbociclib plus
letrozole
Clinical characteristics, n (%)
Palbociclib plus letrozole
Odds ratio p value
With grade 3 or
4 neutropenia (n = 298)
Without grade 3 or
4 neutropenia (n = 146)
Univariate analysis
Received prior chemotherapy
Yes 143 (48.0) 70 (47.9)
No 155 (52.0) 76 (52.1) 1.002 .9935
Previous radiotherapy
Yes 158 (53.0) 78 (53.4)
No 140 (47.0) 68 (46.6) 0.984 .9361
Age
<50 yr 43 (14.4) 20 (13.7)
50–69 yr 181 (60.7) 97 (66.4) 1.152 .6350
≥70 yr 74 (24.8) 29 (19.9) 0.843 .6228
Baseline ECOG performance status
0 176 (59.1) 81 (55.5)
1 or 2 122 (40.9) 65 (44.5) 1.158 .4729
Number of disease sites
1 93 (31.2) 45 (30.8)
2 84 (28.2) 33 (22.6) 0.812 .4473
≥3 121 (40.6) 68 (46.6) 1.161 .5269
Race
White 214 (71.8) 130 (89.0)
Nonwhite 84 (28.2) 16 (11.0) 0.314 <.0001
Ethnicity
Asian 58 (19.5) 7 (4.8)
Non-Asian 240 (80.5) 139 (95.2) 4.799 .0002
Baseline absolute neutrophil countb
≥ Median value 112 (37.6) 111 (76.0)
< Median value 186 (62.4) 35 (24.0) 0.190 <.0001
Multivariate analysis
Ethnicity
Asian 58 (89.2)
Non-Asian 240 (63.3) 2.8916 .0737
Baseline absolute neutrophil countb
≥ Median value 112 (50.2)
< Median value 186 (84.2) 0.1814 <.0001
aNeutropenia was determined based on laboratory tests of absolute neutrophil counts.
bAbsolute neutrophil count median value = 3.68 × 103 per mm3.
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
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with decreased neutrophil count (5.2% in the palbociclib arm
vs. 0% in the placebo arm), and 3.8% (6 of 160 patients) had a
dose reduction associated with febrile neutropenia (1.4% in
the palbociclib arm vs. 0% in the placebo arm). Although the
study protocol defined the toxicities for which dose reductions
were to be made to manage the toxicity, it should be noted
that some reductions were not necessarily due to toxicity
findings.
A landmark analysis using three different landmarks (3, 6,
and 9 months) suggested that in patients receiving palbociclib
plus letrozole, PFS was similar among those who experienced
dose reduction and those who did not (Fig. 4A–C).
A second landmark analysis assessed PFS for patients
who developed palbociclib-associated grade 3/4 neutrope-
nia at 3, 6, and 9 months (supplemental online Fig. 4A–C).
These results suggest that the occurrence of grade 3/4 neu-
tropenia does not appear to compromise efficacy (i.e., PFS
benefit).
Tumor Response: Assessment of Laboratory Data
The investigator-assessed confirmed objective response rate
(ORR) was similar among patients receiving palbociclib,
irrespective of the severity of neutropenia (supplemental online
Table 5). The ORR (95% CI) was 41.6% (32.9%–50.8%) for
patients with maximum grade 1/2 neutropenia, 44.6% (38.9%–
50.5%) for maximum grade 3/4 neutropenia, and 43.7% (38.9%–
48.6%) for any-grade neutropenia. Investigator-assessed con-
firmed clinical benefit response rates (95% CI) were also similar,
irrespective of neutropenia severity, although slightly higher for
patients with maximum grade 3/4 neutropenia (87.6% [83.3%–
91.1%]) versus maximum grade 1/2 neutropenia (82.4% [74.6%–
88.6%]; supplemental online Table 5).
DISCUSSION
This detailed safety analysis of PALOMA-2 showed that the
combination of palbociclib plus letrozole was generally well
tolerated in postmenopausal women with ER+/HER2− ABC
who had not received prior systemic anticancer therapies
for their advanced disease. AEs, including treatment-related
hematologic AEs, are consistent with the known safety pro-
file for palbociclib plus letrozole. Treatment-related hema-
tologic toxicities, including a high incidence of neutropenia,
were manageable by dosing interruption, dose reduction,
cycle delay, and/or standard medical therapy. The clinical
patterns of neutropenia and other hematologic toxicities with
palbociclib were consistent with observations in PALOMA-1 and
PALOMA-3 [13, 14, 16] and rarely led to permanent treatment
discontinuation in PALOMA-2; although neutropenia occurred
at a higher frequency than other AEs, the incidence of febrile
neutropenia remained low (1.8%), and this toxicity did not result
in any permanent treatment discontinuations. Anemia and
thrombocytopenia also occurred more frequently in patients
treated with palbociclib plus letrozole, albeit with a substantially
lower incidence than neutropenia, and those hematologic toxic-
ities were mostly grade 1/2 in severity.
Neutropenia (any grade) occurred at a higher frequency in
patients receiving palbociclib plus letrozole compared with
placebo plus letrozole (95.3% vs. 18.9%). However, this signifi-
cantly higher frequency of neutropenia did not compromise
the duration of treatment, which was longer for patients
receiving palbociclib plus letrozole compared with patients
receiving placebo plus letrozole (19.8 vs. 13.6 months, respec-
tively). The median time to onset of any-grade neutropenia
and grade ≥ 3 neutropenia was 15 days and 28 days, respec-
tively, for patients receiving palbociclib plus letrozole. In this
study, the median duration of grade ≥ 3 neutropenia
(by episode) was 7 days. Although approximately two-thirds
of palbociclib dose reductions were attributed to neutrope-
nia, dose reductions did not appear to compromise PFS,
suggesting that effective therapeutic levels of palbociclib
were maintained. A potential explanation for this observa-
tion is that patients who required dose reductions may
have experienced fewer dose delays, and, consequently, the
exposure over time may have been similar to those patients
who did not require dose reductions. A recent exposure-
response analysis of PALOMA-2 showed that PFS was simi-
lar between Asian and non-Asian patients, even though
Asian patients had more frequent dose reductions [21]. This
finding was likely the result of the average palbociclib expo-
sure being higher in Asian patients because of lower clear-
ance versus non-Asians. Thus, in both of these incidences,
dose reductions may not have necessarily resulted in lower
exposure over time.
Table 3. Hematologic AEsa associated with permanent or
temporary treatment discontinuations and dose reductions
AEs, n (%)
Palbociclib
plus letrozole
(n = 444)
Placebo
plus letrozole
(n = 222)
Permanent discontinuation
Neutropenia 5 (1.1) 0
Neutrophil count decreased 2 (0.5) 0
Temporary discontinuation
Neutropenia 243 (54.7) 2 (0.9)
Neutrophil count decreased 59 (13.3) 1 (0.5)
Leukopenia 28 (6.3) 0
White blood cell count
decreased
17 (3.8) 0
Anemia 9 (2.0) 0
Febrile neutropenia 7 (1.6) 0
Thrombocytopenia 5 (1.1) 1 (0.5)
Platelet count decreased 2 (0.5) 0
Dose reduction
Neutropenia 108 (24.3) 1 (0.5)
Neutrophil count decreased 23 (5.2) 0
Febrile neutropenia 6 (1.4) 0
Leukopenia 5 (1.1) 0
White blood cell count
decreased
4 (0.9) 0
Anemia 2 (0.5) 0
Thrombocytopenia 1 (0.2) 0
Platelet count decreased 1 (0.2) 0
aAll-causality AEs based on AE data (by preferred term) are reported
and include data up to 28 days after last dose of study drug.
Abbreviation: AE, adverse event.
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Findings in the present study showed that clinical charac-
teristics, such as Asian ethnicity and low baseline absolute neu-
trophil counts, may increase the risk of developing grade 3/4
neutropenia. Additionally, an analysis of the Asian subgroup in
PALOMA-2 revealed that Asian patients had lower mean and
median baseline absolute neutrophil counts compared with
non-Asians [22]. These observations highlight the importance
of closely monitoring these patients and intervening with dose
A
B
C
Figure 4. Progression-free survival landmark analysis for patients experiencing palbociclib dose reduction versus no dose reduction.
Landmark set at (A) 3 months, (B) 6 months, and (C) 9 months. Patients with a progression-free survival time ≤ landmarks were
excluded from the corresponding analysis.
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The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.
www.TheOncologist.com
Diéras, Harbeck, Joy et al. 1523
adjustments when indicated. However, because hematologic
AE severity appears to vary by patient, this recommendation
to closely monitor patients for neutropenia should apply to all
patients receiving palbociclib as a means to reduce the inci-
dence or recurrence of more severe grades of neutropenia.
Approximately 11% of patients in the palbociclib plus
letrozole arm received G-CSF to manage neutropenia during
the study. A similar percentage was reported in the PALOMA-
3 study, which was performed in women with HR+/HER2−
ABC with prior progression on endocrine therapy and in
which only a minority of patients (<11%) in the palbociclib
plus fulvestrant arm received G-CSF to manage neutropenia
[20]. It should be noted that G-CSF was administered based
on the investigator’s judgment, as its use was not a protocol
recommendation for the management of neutropenia. Con-
sidering the low incidence of febrile neutropenia and rapid
neutrophil recovery reported in patients administered pal-
bociclib [13, 14, 20], there is no recommendation for prophy-
lactic use of G-CSF or antibiotics.
Neutropenia associated with cytotoxic chemotherapeutic
agents is typically the result of DNA damage and apoptotic
cell death of bone marrow mononuclear cells [15], resulting
in acute onset of neutropenia and a prolonged suppression
of neutrophils [23]. However, neutropenia observed with pal-
bociclib therapy is typically transient, reflecting a cytostatic
effect on neutrophil precursors in the bone marrow, with a
reinitiation of the cell cycle during the 1 week treatment-free
period [13, 15]. Hu et al. demonstrated in tumor cells that
chemotherapeutic agents and palbociclib both inhibited cell
proliferation and induced cellular senescence without cellular
apoptosis, whereas in bone marrow cells, apoptosis was
observed with chemotherapeutic agents but not with pal-
bociclib (i.e., cytotoxic vs. cytostatic) [15]. Consequently, the
palbociclib-free week between dosing cycles helps restore
neutrophil count, whereas dose modification or short inter-
ruptions of therapy can be used to prevent higher grade neu-
tropenia episodes without affecting anticancer efficacy in
tumor cells [15]. The recommended dosing schedule for pal-
bociclib (3 weeks on, 1 week off) provides a safe way to
manage neutropenia without compromising efficacy.
Chemotherapy-induced neutropenia has been associated
with an increased risk of life-threatening infections in patients
with cancer [24, 25], and in this study, overlapping infections
(all grades) in patients with neutropenia (all grades) were
observed in 51.8% of patients in the palbociclib plus letrozole
arm. However, 93.2% of these infections were grade 1/2 in
severity, and no patient in the palbociclib arm experienced a
fatal infection. Moreover, in patients with grade 3/4 neutrope-
nia, 31.2% of patients had an overlapping infection (all grades),
the majority (93.5%) of which were grade 1/2.
Palbociclib appeared to be well tolerated in this study,
resulting in a permanent discontinuation rate due to AEs of
9.7%. However, the observed increased incidence of AEs
could potentially have a negative impact on patient health
and quality of life. Consequently, a recent analysis of
PALOMA-2 was performed using the Functional Assessment
of Cancer Therapy–Breast and EuroQoL–5 Dimension ques-
tionnaires to assess patient-reported health-related quality
of life [26]. Patient responses demonstrated that adding
palbociclib to letrozole therapy maintained health-related
quality of life and was associated with improved pain scores
in treatment-naive postmenopausal women with ER+/HER2−
ABC compared with those treated with letrozole alone. In
particular, no statistically significant difference was observed
for either index score in patients with or without neutrope-
nia [26].
Although the CDK 4/6 inhibitors currently approved for
the treatment of HR+/HER2− advanced or metastatic breast
cancer share similar overall AE profiles, there are several
important differences with respect to hematologic cytopenic
effects [6, 7, 27–29]. For example, whereas both palbociclib
(PALOMA-2) [14] and ribociclib (phase III MONALEESA-2) [30]
had similarly high incidences of any-grade and grade 3/4
neutropenia (80% and 66%, respectively, for palbociclib vs.
74% and 59% for ribociclib), the phase III MONARCH 3 study
showed a relatively lower rate of neutropenia with abe-
maciclib (41% and 21%), which may potentially be due to the
greater potency of abemaciclib against CDK4 versus CDK6
[29]. However, the incidence of diarrhea was much lower for
palbociclib [14] and ribociclib [30] compared with abemaciclib
[29] (26% and 1% for palbociclib and 35% and 1% for
ribociclib vs. 81% and 10% for abemaciclib). Palbociclib also
demonstrated a lower incidence of thrombocytopenia com-
pared with abemaciclib (16% and 2% vs. 36% and 2%) [14,
29]. Because all three of these CDK 4/6 inhibitors have shown
clinical benefit in the treatment of HR+/HER2− ABC [27], the
choice of an appropriate CDK 4/6 agent in clinical practice will
likely be driven by the PFS benefit and safety considerations
given the clinical characteristics of each individual patient.
CONCLUSION
In PALOMA-2, palbociclib in combination with letrozole was
well tolerated, with a safety profile similar to that observed in
previous clinical studies. Neutropenia was the most common
AE associated with palbociclib treatment; however, it rarely
resulted in permanent discontinuation from study treatment,
and the risk of developing febrile neutropenia was low. Consis-
tent with its mechanism of action, palbociclib-induced neutro-
penia was generally transient and readily managed through
dose and treatment schedule adjustments, without the need
for G-CSF support, while appearing to maintain PFS benefits in
most women with ER+/HER2− ABC.
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